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Abstract
Background: Malawi’s national antiretroviral therapy program provides atazanavir/ritonavir–based second line
regimens which cause concentration-dependent rise in indirect bilirubin. We sought to determine if elevated bilirubin,
as a surrogate of atazanavir/ritonavir adherence, can aid in the evaluation of second line virological failure in Malawi.
Methods: We conducted a cross-sectional study of HIV-infected patients ≥15 years who were on boosted protease
inhibitor-based second line antiretroviral therapy for at least 6 months in two urban HIV clinics in Lilongwe, Malawi.
Antiretroviral therapy history and adherence data were extracted from the electronic medical records and blood was
drawn for viral load, complete blood count, total bilirubin, and CD4 cell count at a clinic visit. Factors associated with
virological failure were assessed using multivariate logistic regression model.
Results: Out of 376 patients on second line antiretroviral therapy evaluated, 372 (98.9%) were on atazanavir/ritonavir-
based therapy and 142 (37.8%) were male. Mean age was 40.9 years (SD ± 10.1), mean duration on second line
antiretroviral therapy was 41.9 months (SD ± 27.6) and 256 patients (68.1%) had elevated bilirubin >1.3 mg/dL. Overall,
35 (9.3%) patients had viral load >1000 copies/ml (virological failure). Among the virologically failing vs. non-failing
patients, bilirubin was elevated in 34.3% vs. 72.0% respectively (p < 0.001), although adherence by pill count was similar
(62.9% vs. 60.7%, p = 0.804). The odds of virological failure were higher for adults aged 25–40 years (adjusted odds ratio
(aOR) 2.5, p = 0.048), those with CD4 cell count <100 (aOR 17.5, p < 0.001), and those with normal bilirubin levels (aOR
5.4, p < 0.001); but were lower for the overweight/obese patients (aOR 0.3, p = 0.026). Poor pill count adherence (aOR
0.7, p = 0.4) and male gender (aOR 1.2, p = 0.698) were not associated with second line virological failure.
Conclusions: Among patients receiving atazanavir/ritonavir-based second line antiretroviral therapy, bilirubin levels
better predicted virological failure than pill count adherence. Therefore, strategic use of bilirubin and viral load testing
to target adherence counseling and support may be cost-effective in monitoring second line antiretroviral therapy
adherence and virological failure. Drug resistance testing targeted for patients with virological failure despite elevated
bilirubin levels would facilitate timely switch to third line antiretroviral regimens whenever available.
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Background
Antiretroviral therapy (ART) scale-up in developing coun-
tries reversed upward trends in HIV-associated mortality,
morbidity, and disease transmission (http://www.unaid-
s.org/sites/default/files/country/documents/MWI_narrative
_report_2015.pdf). Despite these improved outcomes in
many patients on ART, some eventually fail first line and
second line treatment resulting in increased morbidity and
mortality for people living with HIV (PLHIV) [1, 2]. Moni-
toring of treatment adherence and treatment failure is a
challenge (http://www.who.int/hiv/pub/arv/adult2010/en/;
http://www.who.int/hiv/topics/treatment/First_Line_ART_-
failure_RLS_metanalysis.pdf [3]), particularly due to the
limited access to viral load testing and genotyping assays [4,
5]. Poor adherence to first line ART often translates to con-
tinued poor adherence to later lines of ART [6, 7]. While
drug resistance contributes to second line virological failure
(VF) [8], poor adherence, often in the absence of drug re-
sistance has been described [9–13]. Therefore, detection of
poor adherence to ART accompanied by targeted adher-
ence counseling and support may lead to better virological
suppression and lower ART switch rates [14, 15].
Approximately 1% of patients in Malawi’s national ART
program were on second line regimens with the majority
(91%) assessed as adherent based on indirect medication
adherence measurements such as pill count and self-
reported missed doses (http://www.unaids.org/sites/default/
files/country/documents/MWI_narrative_report_2015.pdf).
Malawi adopted atazanavir/ritonavir (ATV/r) as the
boosted protease inhibitor (PI/r) of choice in 2013; this
being a switch from lopinavir/ritonavir (LPV/r) used earlier
in its second line ART regimens [16]. ATV/r causes a dose-
dependent indirect hyperbilirubinemia [17–21]. This
biologic phenomenon has the potential, as an inexpensive
surrogate measure of adherence to an ATV/r regimen [22],
to distinguish between non-adherence and drug resistance
as the cause for VF of second line ART regimens.
There is currently limited data describing both second
line VF and whether ATV/r-associated hyperbilirubinemia
might serve as a biologic marker of treatment adherence.
We, therefore, sought to determine the prevalence and
understand the factors associated with VF in a cohort of
HIV-infected ART-experienced Malawians on second line
ART. We also sought to evaluate the role of serum total
bilirubin as a surrogate marker for ATV/r adherence.
Methods
Study setting
This study was conducted at Lighthouse (LH) and Martin
Preuss Centre (MPC) outpatient HIV clinics in Lilongwe,
Malawi. The Lighthouse Trust, operating both LH clinic
and MPC, is the largest provider of adult HIV care for
PLHIV in Malawi. The integrated Tuberculosis(TB)/HIV
care program and Option B+ program for HIV positive
pregnant and breastfeeding women and their families is
based at MPC, while all other services are provided at
both sites. Viral load (VL) monitoring is done according
to Malawi’s national ART guidelines at 6 months following
initiation of a new ART regimen and at 2 years and every
2 years thereafter [16]. First line ART is tenofovir/lamivu-
dine/efavirenz (TDF/3TC/EFV); referred to within the
Malawi National ART Program as 5A) with the potential
use of nevirapine (NVP), abacavir/lamivudine (ABC/3TC)
or zidovudine/lamivudine (AZT/3TC) for toxicity man-
agement ([16], http://www.who.int/hiv/pub/guidelines/
arv2013/download/en/). Second line ART is AZT/3TC or
TDF/3TC plus ATV/r. Lopinavir/ritonavir (LPV/r) is
available as a substitute for ATV/r’s toxicity or when TB
treatment is required ([16], http://www.who.int/hiv/pub/
guidelines/arv2013/download/en/).
Study population and design
Study participants were identified from the clinics’ Elec-
tronic Medical Records (EMR) systems. They included
HIV-infected patients aged ≥15 years attending the MPC
and LH outpatient HIV clinics who were receiving PI/r-
based second line ART for at least 6 months and with HIV-
1 RNA (VL) results. At their regularly scheduled outpatient
visits between December 2013 and May 2014, blood was
collected for VL, complete blood count (CBC), CD4 cell
count, renal function tests and liver panel. We then con-
ducted a cross-sectional study of these participants to as-
sess the factors associated with second line VF within these
two facilities. At the time of evaluation, it was estimated
that approximately 400 individuals had been initiated on
second line therapy in Lighthouse clinics (approximately
2% of the Lighthouse ART population). This proportion is
slightly higher than the national average (1% of the national
ART population) because Lighthouse, as a center of excel-
lence, serves as a referral centre as well as one of the first
and largest providers of ART services in the country.
Sources of data
All HIV-infected individuals receiving care at LH and
MPC were registered in the EMR systems, as described
previously ([23], https://github.com/openmrs), where de-
tailed patients’ records collected were accessible through
printed reports or directly via the touchscreen terminals
in the reception and clinical consultation rooms. These
systems also guided the healthcare workers according to
Malawi’s clinical HIV guidelines and facilitated medica-
tion prescribing and dispensing while performing clinical
calculations (e.g., drug adherences). For this study,
socio-demographic, clinical and laboratory data, body
weight, ART treatment history and previous trends in
antiretroviral drug adherence (through pill counts) for
individuals on second line ART were obtained from the
EMR systems and patients’ medical charts.
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Laboratory evaluations
All the blood samples were processed at the University of
North Carolina Research Project Laboratory in Lilongwe.
VL was measured using the Abbott Real Time HIV-1
assay system (https://www.abbottmolecular.com/us/prod-
ucts/realtime-hiv-1.html). CD4 cell counts were deter-
mined by flow cytometry using the Becton Dickinson
FACSCount system (Becton Dickinson, Mountain View,
California, USA). Complete blood count (CBC) was ana-
lyzed in the Beckman Coulter AcT 5diff Cap Pierce
hematology analyzer (Beckman Coulter, Miami, FL), while
liver and renal function tests were analyzed in the Roche
Cobas C 311 chemistry analyzer. Laboratory results were
graded according to the National Institute of Health Div-
ision of AIDS (DAIDS) Tables for grading the severity of
adult and pediatric adverse events: Version 2.0 - Novem-
ber 2014 (http://rsc.tech-res.com/Document/safetyand-
pharmacovigilance/DAIDS_AE_GRADING_TABLE_v2_
NOV2014.pdf).
Variables
The primary outcome was the proportion of patients on sec-
ond line PI/r-based ART with virological failure (VF) defined
as VL >1000 copies/ml per Malawi’s guidelines [16] based
on a single blood draw regardless of reported pill count ad-
herence. The primary predictor variable was the cumulative
PI/r pill count adherence, whenever possible, which is the
average PI/r pill count adherence for at least 6 months prior
to the VL sample collection date. This is calculated as:
(pill adherence) = (pill sum difference) / (pill use interval),
where;
➢Pill sum difference = (previous pill sum) – (current
pill count)
➢Previous pill sum = (pill count prior to supply
visit) + (pills dispensed at supply visit)
➢Pill use interval = (no. of days used pills since last
supply) X (number of PI/r pills taken per day)
We defined good adherence for desirable virological
outcome (VL ≤ 1000 copies/ml) in this study as average
pill count adherence of ≥95% and ≤105% [24]. The other
variables of interest included age, gender, body mass
index (BMI), CD4 cell count, total bilirubin, duration on
ART, duration on second line ART, PI/r base, and nu-
cleoside reverse transcriptase inhibitor (NRTI) backbone.
All study participants analyzed had VL measurements
for determination of VF. We also used a VL threshold of
400 copies/ml to calculate the prevalence rate of VF for
comparison to other studies.
Statistical analysis
Descriptive statistics were used to summarize the study
population characteristics and the overall prevalence of
second line VF. Continuous variables were summarized
using mean and standard deviation (SD); categorical var-
iables were summarized using frequency and percent
(%). The distribution of viral load measurement in our
study sample was non-normal due to the high propor-
tion of individuals that were successfully suppressed.
Other variables were normally distributed. Associations
between socio-demographic or HIV-related variables
and VF were assessed using the χ2 test for categorical
variables and the Student’s t-test for continuous vari-
ables. We used univariate logistic regression analysis to
identify factors associated with VF, in addition to the
known determinants of VF [25, 26]. Sensitivity, specifi-
city, positive and negative predictive values using biliru-
bin testing to screen for VF were also calculated. We
then used a multivariate logistic regression model fitted
through backward selection of variables to assess the ad-
justed effect of predictor variables on the primary out-
come (VF). Age, gender, pill count adherence and time
on ART were included a priori to the model. Variance
inflation factors were computed for each of the predictor
variable to exclude from the model covariates that dem-
onstrated collinearity. All analyses were done in STATA
SE version 12.0 (College Station, Texas). Statistical sig-
nificance was considered at a two-sided α-level of 0.05.
Results
Out of 376 HIV-infected patients on second line ART eval-
uated, 372 (98.9%) were on ATV/r-based therapy at the
time of study and 142 (37.8%) were male (Table 1). The
mean age was 40.9 years (SD ± 10.1), the mean duration on
second line ART was 41.9 months (SD ± 27.6), and the
mean duration on ATV/r-based second line therapy was
9.1 months (SD ± 1.5). Two hundred and twenty nine
(60.9%) patients appeared to have averaged good adherence
by pill count over the previous 6 months while 256 (68.1%)
patients had elevated bilirubin (>1.3 mg/dL). Of the 376 in-
dividuals with VL data, 35 (9.3%) had VL > 1000 copies/ml,
37 (9.8%) had VL ≥ 400 copies/ml while 93 (24.7%) had VL
≥40 copies/ml.
Overall, out of 35 (9.3%) patients who had Malawi-
defined VF (VL > 1000 copies/ml) while on second line
ART (Table 2), the majority (60%) were aged 25–40 years
old in these two urban HIV clinics. Among the virologic-
ally failing vs. non-failing patients, those failing therapy
were younger (mean age of 36 vs. 41.4 years, p = 0.0025),
had lower CD4 cell count (mean of 206 vs. 466 cells/mm3,
p < 0.001), and had significantly lower bilirubin levels (1.0
vs. 2.4 mg/dL, p < 0.001). Bilirubin was elevated in 34.3%
vs. 72.0% respectively (p < 0.001), although adherence by
pill count were similar (62.9% vs. 60.7%, p = 0.804). The
distributions of other population characteristics were simi-
lar among the virologically failing vs. non-failing patients.
We observed medium correlation between VF and World
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Health Organization (WHO) defined immunological fail-
ure (CD4 cell count <100 cells/mm3) (r = 0.3119, p-value
<0.001).
The sensitivity and specificity of using bilirubin testing
at the 1.3 mg/dL level to screen for VF was 65.7% and
72% respectively with a false negative rate of 34.3% and
false positive rate of 28%. Bilirubin testing had a negative
predictive value (NPV) of 95.3% and a positive predictive
value (PPV) of 19.5%. The positive likelihood ratio (PLR)
was 2.3 while the negative likelihood ratio (NLR) was
0.5. Using higher bilirubin cutpoints increased sensitivity
but reduced specificity (Table 3).
Univariate and multivariate logistic regressions identified
factors associated with VF (Table 4). The odds of VF were
higher for adults aged 25–40 years (adjusted Odds Ratio
(aOR) 2.5, p = 0.048), those with CD4 cell count <100 cells/
mm3 (aOR 17.5, p < 0.001), and those with normal bilirubin
levels (aOR 5.4, p < 0.001); but were lower for the over-
weight/obese patients (aOR 0.3, p = 0.026). Poor adherence
by pill count (aOR 0.7, p = 0.4) and male gender (aOR 1.2,
p = 0.698) were not associated with increased risk of VF.
Similarly, time on second line ART (aOR 1; p = 0.921) and
time on ATV/r (aOR 0.9; p = 0.409) were not associated
with increased risk of VF and did not demonstrate collin-
earity. Additionally, using bilirubin as a continuous variable,
the odds of VF were 0.31 less for every unit rise in total
bilirubin (p-value <0.005).
Discussion
We found a surprisingly low prevalence rate of VF (9.3%)
among patients retained on second line ART at these two
urban outpatient HIV clinics in Lilongwe, Malawi. Import-
antly, we identified several easily measureable factors pre-
dicting VF including bilirubin levels, CD4 cell count, BMI
and age. Bilirubin testing, as a biologic marker for adher-
ence to ATV/r-based therapy, may be an effective tool in
evaluating patients for ART adherence and VF prior to the
more expensive and less available genotype resistance test-
ing and third line therapy.
The prevalence rate of second line VF was lower in this
study than reported elsewhere [10], although different VL
thresholds were used to make the comparison. We used a
VL threshold of 1000 copies/ml to define VF to align to
Malawi’s guidelines whereas other studies [2, 27] used a
lower VL threshold of 400 copies/ml to define failure.
Despite the sensitivity of VF rates to VL thresholds for
failure definition [27], our study yielded low rates of 9.8%
for VL thresholds of 400 copies/ml. ATV/r which is dosed
once daily may have fewer side effects than LPV/r, and
this may favor better treatment adherence and virological
suppression as evidenced in this study [16, 28]. Previous
studies that reported higher rates of VF predominantly
used LPV/r as the PI/r of choice [10, 29]. However, we do
not expect differences in therapeutic responses to LPV/r
Table 1 Population characteristics of HIV-infected patients on
second line ART in two urban HIV clinics in Lilongwe, Malawi
Characteristics (Categorical) N = 376
n (%)
Age in years
15–24 27 (7.2)
25–40 161 (42.8)
> 40 188 (50.0)
Gender
female 234 (62.2)
male 142 (37.8)
CD4 cell count (cells/mm3)
≥ 100 362 (96.3)
< 100 12 (3.2)
Virological failure (>1000 copies/ml)
yes 35 (9.3)
no 341 (90.7)
BMI (kg/m2)
normal 207 (55.1)
underweight 25 (6.7)
overweight/obese 144 (38.3)
Pill count adherence
good (95% - 105%) 229 (60.9)
poor (<95% or >105%) 147 (39.1)
Current boosted protease inhibitor
atazanavir/ritonavir 372 (98.9)
lopinavir/ritonavir 4 (1.1)
Current NRTI backbone
ABC/3TC 5 (1.3)
AZT/3TC 67 (17.8)
TDF/3TC 303 (80.6)
d4T/3TC 1 (0.3)
Reason for ART initiation
WHO clinical stage III/IV 283 (75.3)
CD4 cell count below threshold 74 (19.7)
pregnancy/lactating 3 (0.8)
Total bilirubin level
elevated (>1.3 mg/dL) 256 (68.1)
normal (≤1.3 mg/dL) 118 (31.4)
Characteristics (Continuous) N = 376
Mean (SD)
age (years) 40.9 (10.1)
CD4 cell count (cells/mm3) 442.6 (245.8)
time on ART (months) 89.9 (34.4)
time on second line ART (months) 41.9 (27.6)
time on ATV/r base (months) 9.1 (1.5)
BMI (kg/m2) 24.7 (5.0)
total bilirubin (mg/dL) 2.2 (1.6)
hemoglobin (g/dL) 12.9 (2.1)
Numbers and proportions may not add up due to missing data
Ongubo et al. BMC Infectious Diseases  (2017) 17:461 Page 4 of 10
Table 2 Characteristics of HIV-infected patients with second line virological failure in two urban HIV clinics in Lilongwe, Malawi
Characteristics (Categorical) Viral load ≤ 1000
N = 341
n(column%)
Viral load > 1000
N = 35
n(column%)
Total
N = 376
n(column%)
p-value
Age in years
15–24 22 (6.5) 5 (14.3) 27 (7.2)
25–40 140 (41.1) 21 (60.0) 161 (42.8)
> 40 179 (52.5) 9 (25.7) 188 (50.0) 0.005*
Gender
female 212 (62.2) 22 (62.9) 234 (62.2)
male 129 (37.8) 13 (37.1) 142 (37.8) 0.936
CD4 cell count (cells/mm3)
≥ 100 335 (98.5) 27 (79.4) 362 (96.8)
< 100 5 (1.5) 7 (20.6) 12 (3.2) <0.001*
BMI (kg/m2)
normal 183 (53.7) 24 (68.6) 207 (55.1)
underweight 21 (6.2) 4 (11.4) 25 (6.7)
overweight/obese 137 (40.1) 7 (20) 144 (38.3) 0.031*
Pill count adherence
good (95% - 105%) 207 (60.7) 22 (62.9) 229 (60.9)
poor (<95% or >105%) 134 (39.3) 13 (37.1) 147 (39.1) 0.804
Current boosted protease inhibitor
atazanavir/ritonavir 338 (99.1) 34 (97.1) 372 (98.9)
lopinavir/ritonavir 3 (0.9) 1 (2.9) 4 (1.1) 0.325*
Current NRTI backbone
ABC/3TC 4 (1.2) 1 (2.9) 5 (1.3)
AZT/3TC 61 (17.9) 6 (17.1) 67 (17.8)
TDF/3TC 275 (80.7) 28 (80) 303 (80.6)
d4T/3TC 1 (0.3) 0 (0) 1 (0.3) 0.583*
Reason for ART initiation
WHO clinical stage III/IV 254 (77.9) 29 (85.3) 283 (78.6)
CD4 count below threshold 69 (21.2) 5 (14.7) 74 (20.6)
pregnancy/lactating 3 (0.9) 0 (0) 3 (0.8) 0.633*
Total bilirubin level
elevated (>1.3 mg/dL) 244 (72.0) 12 (34.3) 256 (68.5)
normal (≤1.3 mg/dL) 95 (28.0) 23 (65.7) 118 (31.6) <0.001
Characteristics (Continuous) Viral Load ≤ 1000 Viral Load > 1000 p-value
Mean (SD) Mean (SD) Total
age (years) 41.4 (10.0) 36.0 (9.5) 376 0.0025
CD4 cell count (cells/mm3) 466.3 (241.2) 205.6 (146.5) 374 <0.001
time on ART (months) 90.1 (34.9) 88.5 (29.4) 372 0.795
time on second line ART (months) 42.5 (27.7) 35.5 (25.9) 376 0.1516
time on ATV/r base (months) 9.1 (1.5) 9.0 (1.8) 372 0.7069
BMI (kg/m2) 24.9 (5.1) 23.2 (4.7) 376 0.0516
total bilirubin (mg/dL) 2.4 (1.6) 1.0 (1.1) 374 <0.001
hemoglobin (g/dL) 13 (2.1) 12.1 (1.5) 376 0.0144
*denotes Fisher’s exact test
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Table 3 Association of different bilirubin cut-off levels with second line virological failure
Bilirubin levels* Sensitivity Specificity Positive Predictive Value Negative Predictive Value
1.3 (Lab Upper Limit of Normal) 65.7 72 19.5 95.3
<2.08 (DAIDS Toxicity Grade < =1) 85.7 49.9 15 97.1
<3.38 (DAIDS Toxicity Grade < =2) 94.3 20.1 10.9 97.1
<6.5 (DAIDS Toxicity Grade < =3) 100 3.24 9.6 100
*Bilirubin values above represent the cut-offs corresponding with DAIDS Version 2.0 toxicity reporting requirements
Table 4 Factors associated with second line virological failure in two urban HIV clinics in Lilongwe, Malawi
Un-adjusted Adjusted
Characteristics Odds Ratios p-value Odds Ratios p-value
Age in years (at time of study evaluation)
> 40 Referent
25–40 3 0.008 2.5 0.048
15–24 4.5 0.012 1.5 0.611
age, per each additional year 0.9 0.003
age at second line ART initiation, per additional year <1.0 0.008
Gender
female Referent
male <1.0 0.936 1.2 0.698
Total time on ART, per additional month <1.0 0.794
Time on second line ART, per additional month <1.0 0.154 1 0.921
Time on ATV/r, per additional month <1.0 0.706 0.9 0.409
BMI (kg/m2)
normal Referent
underweight 1.5 0.525 0.4 0.235
overweight/obese 0.4 0.034 0.3 0.026
Current boosted protease inhibitor
ATV/r Referent
LPV/r 3.3 0.305
Current NRTI backbone
TDF/3TC Referent
AZT/3TC <1.0 0.942
ABC/3TC 2.5 0.429
d4T/3TC 1
CD4 cell count (cells/mm3)
≥ 100 Referent
< 100 17.4 <0.001 17.5 <0.001
Pill count adherence
good (95% - 105%) Referent
poor (<95% or >105%) 0.9 0.804 0.7 0.4
Total bilirubin, per unit rise (mg/dL) 0.3 <0.001
Total bilirubin level
elevated (>1.3 mg/dL) Referent
normal (≤1.3 mg/dL) 4.9 <0.001 5.4 <0.001
Variables included in the multivariate analysis that are not known predictors of second line ART failure had p-values <0.05 in the univariate analysis.
Multicollinearity was assessed using variance inflation factors
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versus ATV/r [30]. Improved access to second line ART
in Malawi ([2], http://www.who.int/hiv/pub/guidelines/
arv2013/download/en/) also may potentially explain the
improved virological outcomes evidenced in this study.
Objective biologic measures of ART adherence are more
reliable in predicting poor adherence and VF than pill
count or patient’s self-report, which often over-estimate
adherence levels [29, 31–35]. Therefore, our finding that
normal bilirubin values in the setting of ATV/r-based
therapy better predicted treatment failure than pill count
is not surprising and supports the use of bilirubin as a sur-
rogate for ATV/r adherence and response [36]. Both the
lower mean bilirubin and the 2.3 times increased risk for
virologically failing patients highlights the usefulness of
this test in monitoring second line treatment failure. Pa-
tients treated with ATV/r have an increase in unconju-
gated and total bilirubin levels due to the concentration-
dependent ATV/r inhibition of the enzyme uridine di-
phosphate glucuronosyltransferase 1A1 (UGT1A1) re-
sponsible for bilirubin conjugation [17–19]. Despite
transient fluctuations of serum bilirubin levels over time,
the elevation often remains stable for at least two years
after initiation of ATV/r [36] making it useful for adher-
ence monitoring in ART-experienced patients [20, 37]. In
countries using ATV/r based second line therapy, a cost-
effective algorithm incorporating targeted bilirubin and
drug resistance testing into routine VL monitoring could
be developed to monitor second line VF and promote
treatment switch. In that algorithm, patients with poor ad-
herence based on low bilirubin levels are targeted for in-
tensive adherence counseling and support. Among those
with elevated bilirubin and hence presumed good adher-
ence, in addition to standard adherence counseling, drug
resistance assays would be conducted to detect potential
drug resistance. Only those failing treatment due to resist-
ance mutations would switch to third line ART. As resist-
ance testing and third line ART are relatively expensive,
such an algorithm would address adherence issues, target
those most likely to have resistance, and more promptly
identify those with resistance in need of third line treat-
ment. This strategy may potentially yield good virological
outcomes [38] and increase survival rates [39, 40] in this
target population. As fewer samples for resistance test-
ing would be taken from patients failing second line
ART simply due to poor adherence, this would in-
crease the proportion of samples with significant re-
sistance mutations where an effective third line
treatment regimen would need to be determined.
Lower CD4 cell count was significantly associated with
VF in this study. A previous study conducted within Mala-
wi’s national ART program had indicated an association of
lower CD4 cell count (<100cells/ml) with high levels of
first line ART resistance, possibly contributing to second
line ART failure [41]. However, studies in other resource-
limited settings have demonstrated poor positive predict-
ive values of WHO CD4 cell count criteria (<100cells/ml)
for virological failure, with the potential for unnecessary
ART switch [42–45]. Adults aged 25–40 years old, being
majority among those failing therapy in these facilities, in-
dependently predicted VF thus supporting findings from
other studies [46]. These individuals are more likely to
miss clinic appointments and hence less likely to be adher-
ent to ART [47]. Similarly, increasing age may be associ-
ated with greater maturity and understanding of health
issues, and established lifestyles. These factors may likely
influence health-seeking behaviors, long-term adherence
to ART and virological suppression. We may not have
seen a significant relationship in adolescents aged 15–
24 years old due to small sample size of this age group.
Body mass index (BMI) frequently used for monitoring
clinical progression of HIV/AIDS demonstrated an associ-
ation with VF. Low BMI has been linked with HIV-
associated morbidity and mortality [2], whereas weight
gain while on ART may indicate optimal medication ad-
herence. Despite varied views on the use of clinical
markers to predict VF [48, 49], high BMI (overweight and
obesity) was significantly associated with VL ≤1000, per-
haps relating the general health improvements with favor-
able ART response in this population. However, the large
proportion of second line ART patients classified as over-
weight or obese in this study may pose future health con-
cern due to non-communicable diseases. Gender was not
independently associated with VF in spite of the perceived
vulnerabilities of men to ART failure [50–52]. Similarly,
the duration of second-line ART was not associated with
VF [2], probably reflecting the high genetic barrier to viral
resistance accorded by protease inhibitors in the context
of good adherence [53].
The findings of this study should be considered in light
of their strengths and limitations. Firstly, there is the likeli-
hood of selection bias. Only participants receiving second
line ART and who presented to the clinic during the period
of the study were included for analysis. Those missing
visits, and hence at higher risk for VF due to poor adher-
ence to clinic appointments and missed doses, were not in-
cluded for the analysis. Therefore, our results represent VF
rates among persons on second line ART retained in care
and may underestimate the true rate of treatment failure.
Secondly, this analysis was based on cross-sectional obser-
vational data thereby limiting our ability to determine a
causal relationship between laboratory parameters used to
monitor second-line ART adherence and VF. Similarly,
baseline values which would have improved our under-
standing of the factors associated with VF by looking at the
temporal associations of clinical and laboratory parameters
with second line ART, were unavailable. However, because
LH and MPC outpatient HIV clinics are major public pro-
viders of second line ART in Malawi’s capital city of
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Lilongwe, the findings in this study could be generalizable
for ART programs in Malawi and other regions with a gen-
eralized HIV epidemic in urban populations. Thirdly, pill
count adherence may be misleading particularly in
treatment-experienced patients in whom social desirability
bias may encourage pill dumping and lead to overesti-
mation of medication adherence (>105%). Pill count adher-
ence was overestimated in 73 (49.7%) of those with poor
pill count adherence estimates. However, just like sub-
optimal pill count adherence (<95%), overestimation of ad-
herence has been associated with increased risk of VF [54]
thus justifying their inclusion as poor pill count adherence
measurements in this analysis. Fourthly, many of the partic-
ipants were highly experienced on second line ART
(42 months) but had much shorter exposure to ATV/r
(9 months) due to Malawi’s recent adoption of ATV/r in
second line ART regimens. Therefore, we are unable to
comment on whether our results would be similar for those
with longer duration of ATV/r exposure and if there were
transient fluctuations of serum bilirubin over time [36].
Lastly, genotypic resistance testing that is important when
selecting alternative therapeutic regimens [55] was not
available to characterize the resistance profiles of those with
VF, although development of resistance to PIs is uncom-
mon [9]. Resistance testing would have allowed more thor-
ough evaluation of the associations between virological
failure, ATV/r adherence and bilirubin levels.
Conclusions
Given the limited access to VL monitoring, drug resist-
ance testing and third line treatment regimens in sub-
Saharan Africa, strategies for cost-effective delivery of
ART services are needed. Bilirubin, as a surrogate marker
for ATV/r adherence among patients receiving second
line therapy, better predicted VF than pill count adher-
ence. Strategic use of bilirubin and VL testing to target ad-
herence counseling and support may be cost-effective in
monitoring second line ART adherence and VF particu-
larly for adults aged 25–40 years and those with CD4 cell
count <100 cells/mm3. Therefore, individuals with normal
or low bilirubin levels and VF (VL >1000 copies/ml) while
on ATV/r-based second line ART would benefit from in-
tensive adherence counseling and support to help
optimize the duration of second line treatment regimens.
Drug resistance testing targeted for patients with viro-
logical failure despite persistently elevated bilirubin levels
would facilitate timely switch to third line antiretroviral
regimens whenever available.
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